Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer.
J Cancer Res Clin Oncol
; 149(16): 15095-15102, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-37626173
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Carcinoma, Non-Small-Cell Lung
/
Lung Neoplasms
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Year:
2023
Type:
Article